PROGRESS OF SARS-CoV-2 IN PATIENTS WITH HIV/AIDS AT THE HOSPITAL FOR TROPICAL DISEASES

Lý Võ Triều, Tân Phạm Văn, Nhi Võ Thị Hồng, Hiếu Vũ Thị

Main Article Content

Abstract

Background: COVID-19 emerged in Wuhan, China, at the end of 2019 and led to a global pandemic. Patients with HIV/AIDS are classified as a high-risk population during the COVID-19 pandemic. Aims: To describe the progression of SARS-CoV-2 PCR results in HIV-infected patients with COVID-19 and identify factors related to SARS-CoV-2 virus clearance. Objectives and Methods: A descriptive cross-sectional study, sampling COVID-19 patients with HIV/AIDS aged 16 years and older, treated at the Hospital for Tropical Diseases from November 2021 to March 2023. Results: A total of 147 COVID-19 cases in HIV/AIDS patients were analyzed, with an average age of 36.9 ± 10.1 years. At the time of admission, 95.2% of patients had a positive SARS-CoV-2 PCR test. The SARS-CoV-2 PCR positivity rate after 14 days of hospitalization was 66.7%. Two patients remained positive for SARS-CoV-2 PCR on day 49 (Ct: 22.95) and day 56 (Ct: 33). The group with a positive SARS-CoV-2 PCR had lower CD4 counts, ARV treatment rates, and SARS-CoV-2 antiviral drug usage compared to the group with a negative SARS-CoV-2 PCR. The mortality rate in our study was 34.7%. Conclusion: The study found that 95.2% of patients had a positive SARS-CoV-2 PCR test at the time of admission, and the PCR positivity rate decreased to 66.7% after 14 days of hospitalization. Two patients remained positive for SARS-CoV-2 PCR after 35 days of hospitalization. Factors associated with clearance of SARS-CoV-2 include low CD4 cell count, ARV treatment, and the treatment with anti-SARS-CoV-2.

Article Details

References

1. World Health Organization. Viet Nam Situation. 2023. Accessed November 10th, 2023. https://covid19.who.int/region/wpro/country/vn
2. A EBR, Cunningham TD, Hair PS, Shah T, Cunnion KM, Troy SB. Effects of Well-Controlled HIV Infection on Complement Activation and Function. J Acquir Immune Defic Syndr. Sep 1 2016;73(1):20-6. doi:10.1097/QAI. 0000000000001079
3. Ho HE, Peluso MJ, Margus C, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. J Infect Dis. Feb 13 2021;223(3):403-408. doi:10.1093/infdis/jiaa380
4. Wei Guo, Fangzhao Ming, Yu Dong, et al. A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China. 2020;doi:http://dx.doi.org/10.2139/ssrn.3550029
5. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. May 7 2020;382(19):1787-1799. doi:10.1056/NEJMoa2001282
6. Bộ Y tế. Quyết định số 5968/QĐ-BYT ngày 31/12/2021. Hướng dẫn điều trị và chăm sóc HIV/AIDS. 2021:122 - 124.
7. Bộ Y tế. Số: 2671/QĐ-BYT. Quyết định về việc ban hành hướng dẫn chẩn đoán và điều trị COVID-19. 2023:9-12.
8. Obirikorang C, Quaye L, Acheampong I. Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings. BMC Infect Dis. Jun 7 2012;12:128. doi:10.1186/1471-2334-12-128
9. Meiring S, Tempia S, Bhiman JN, et al. Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With HumanImmunodeficiency Virus (HIV), South Africa. Clin Infect Dis. Aug 24 2022;75(1):e144-e156. doi:10.1093/cid/ciac077
10. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. Feb 27 2003;348(9):867-8. doi:10.1056/NEJM200302273480923